再鼎医药（09688）今日盘中大涨5.39%，引发市场广泛关注。此次股价上涨主要受到公司2024年销售效率大幅提升的利好消息推动。
据报道，再鼎医药2024年销售人效增幅达到41%，首次突破200万元大关。这一显著提升反映了公司商业化能力的增强，特别是其重磅新药卫伟迦®的成功上市和快速放量。卫伟迦®作为治疗重症肌无力的创新药物，在2024年实现了9,360万美元的收入，占公司总产品收入的四分之一。
值得注意的是，再鼎医药在商业化团队人数仅增长7%的情况下，实现了总产品收入49%的增长。这种高效的商业化策略不仅提升了公司的盈利能力，也增强了投资者对公司未来发展的信心。随着卫伟迦®进一步放量，以及公司其他产品线的持续发展，市场普遍看好再鼎医药在2025年的业绩表现，预计公司有望进一步提高销售效率，逐步接近盈利目标。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.